Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07605052

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight. Participant will get either cagrilintide B or cagrilintide D injections. Which treatment participant will get is decided by chance. Participant will be in this clinical study for about 14 weeks.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Celerion, Phoenix

Tempe, Arizona, 85283, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Age 18-64 years (both inclusive) at the time of signing informed consent.
  • Male or female (sex assigned at birth).
  • Body mass index (BMI) between 27.0 and 34.9 kilogram per meter square (kg/m^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Key Exclusion Criteria:

  • Previous dosing of marketed or non-marketed amylin-agonists (a).
  • Any condition, unwillingness or inability which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol (a).
  • As declared by the participant, reported in the medical records or at the investigator's discretion.

Treatment and study plan

Cagrilintide B

Drug

Cagrilintide B will be administered subcutaneously.

Cagrilintide D

Drug

Cagrilintide D will be administered subcutaneously.

Primary outcomes

  1. AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide

    Time frame: From Pre-dose at Day 29 to Day 36

    Measured as hour*nanomole per liter (h*nmol/L).

  2. Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 5th dosing of cagrilintide

    Time frame: From Pre-dose at Day 29 to Day 36

    Measured as nanomole per liter (nmol/L).

Secondary outcomes

  1. AUCss: area under the total cagrilintide concentration-time curve at steady state after 4th dosing of cagrilintide

    Time frame: From Pre-dose at Day 22 to Day 29

    Measured as h*nmol/L.

  2. Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 4th dosing of cagrilintide

    Time frame: From Pre-dose at Day 22 to Day 29

    Measured as nmol/L.

  3. AUCss: area under the total cagrilintide concentration-time curve at steady state after 1st dosing of cagrilintide

    Time frame: From Pre-dose at Day 1 to Day 8

    Measured as h*nmol/L.

  4. Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 1st dosing of cagrilintide

    Time frame: From Pre-dose at Day 1 to Day 8

    Measured as nmol/L.

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

Investigation of Pharmacokinetics of Two Different Presentations of Cagrilintide in Participants With Overweight and Obesity

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 22, 2026
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.